Centrillion Technology Holdings Ltd.

Centrillion Technology Holdings Ltd. develops innovative DNA analysis solutions, focusing on rapid pathogen detection and genomic sequencing to enhance diagnostics in healthcare and research sectors. Founded in 2009 in Palo Alto, US, Centrillion Technology Holdings Ltd. specializes in advanced DNA analysis.

The company has engaged in three deals, with its most recent deal occurring on July 31, 2018. Wei Z is the founder and serves as the CEO, having previously founded other companies in the technology sector. Centrillion Technologies specializes in advanced DNA analysis through a suite of innovative products designed for rapid pathogen detection and genomic sequencing. Their flagship offerings include the VirusHunter™ assays, enabling fast detection and viral sequencing of pathogens such as SARS-CoV-2 and Influenza A and B, using a multiplex approach that requires only five copies of the target virus for detection.

Additionally, the company provides ligation and extension-based genotyping assays for high-quality human genotyping results, along with spatial transcriptomics technology that allows for quantitative detection of numerous RNA targets at a micron-scale resolution. These solutions are particularly geared towards clinical laboratories and research institutions, facilitating improved public health responses and epidemiological studies. Centrillion's products are marketed primarily in North America and Europe, assisting healthcare providers, research institutions, and commercial laboratories in enhancing diagnostic capabilities and advancing genomics research. Centrillion Technologies operates on a model that supports clinical and research testing services, generating revenue primarily through diagnostic assays and genomic sequencing services.

Transactions are typically structured through partnerships with clinical laboratories, such as Molecular Vision laboratories, which utilize Centrillion's technology to offer COVID-19 and coinfection testing to healthcare providers and patients. The company's pricing strategy accommodates various testing needs, including comprehensive genomic sequencing services like the VirusHunter™ ARTIC SARS-CoV-2 Whole Genome Sequencing Assay, designed for high-throughput applications. By integrating their sophisticated technology into existing laboratory workflows, Centrillion delivers cost-effective solutions that enhance the speed and accuracy of genomic analysis, thereby meeting the demands of their diverse client base in the healthcare sector. Centrillion Technology Holdings Ltd.

plans to launch new products aimed at enhancing genomic sequencing capabilities, with specific timelines for these releases yet to be announced. The company aims to expand its market presence into Asia and South America by 2025. Recent funding from a venture round in July 2018, led by We Doctor, will support these initiatives as the company continues to develop its product offerings and establish partnerships in the targeted regions.